Correlates of the preoperative level of CA125 at presentation of ovarian cancer

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 462-468

  Cramer, Daniel W ^a   Vitonis, Allison F ^a   Welch, William R ^a   Terry, Kathryn L ^a   Goodman, Annekathryn ^b   Rueda, Bo R ^b   Berkowitz, Ross S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BMI; CA125; Ovarian cancer; Parity

Indexed keywords

CA 125 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; APPENDECTOMY; ARTICLE; ASCITES; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COLITIS; CORRELATION ANALYSIS; ETHNICITY; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HUMAN; JEW; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PARITY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE;

CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MASSACHUSETTS; MIDDLE AGED; NEW HAMPSHIRE; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 78149360547     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.028     Document Type: Article

References (30)

1. R.C. Bast Jr., T.L. Klug, E. St. John, E. Jenison, J.M. Niloff, and H. Lazarus A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
2. R.E. Buller, M.L. Berman, J.D. Bloss, A. Manetta, and P.J. DiSaia Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival Gynecol Oncol 47 1992 87 92
3. A. Gadducci, P. Zola, F. Landoni, T. Maggino, E. Sartori, and T. Bergamino Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study Gynecol Oncol 58 1995 42 47
4. M.S. Schilthuis, J.G. Aalders, J. Bouma, H. Kooi, G.J. Fleuren, and P.H. Willemse Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence Br J Obstet Gynaecol 94 1987 202 207
5. E.V. Hogdall, L. Christensen, S.K. Kjaer, J. Blaakaer, A. Kjaerbye-Thygesen, and S. Gayther CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study Gynecol Oncol 104 2007 508 515
6. B.C. Cooper, A.K. Sood, C.S. Davis, J.M. Ritchie, J.I. Sorosky, and B. Anderson Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer Obstet Gynecol 100 2002 59 64
7. J.P. Geisler, G.A. Miller, T.H. Lee, R.M. Harwood, M.C. Wiemann, and H.E. Geisler Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma J Reprod Med 41 1996 140 142
8. K.L. Terry, L. Titus-Ernstoff, J.R. McKolanis, W.R. Welch, O.J. Finn, and D.W. Cramer Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer Cancer Epidemiol Biomarkers Prev 16 2007 30 35
9. F. Medeiros, M.G. Muto, Y. Lee, J.A. Elvin, M.J. Callahan, and C. Feltmate The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 2006 230 236
10. E. Kolwijck, C.M. Thomas, J. Bulten, and L.F. Massuger Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature Int J Gynecol Cancer 19 2009 1335 1338
11. A.P. Makar, G.B. Kristensen, J. Kaern, O.P. Bormer, V.M. Abeler, and C.G. Trope Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis Obstet Gynecol 79 1992 1002 1010
12. F. Zanaboni, F. Vergadoro, M. Presti, P. Gallotti, F. Lombardi, and G. Bolis Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma Gynecol Oncol 28 1987 61 67
13. L.A. Hefler, A.C. Rosen, A.H. Graf, M. Lahousen, M. Klein, and S. Leodolter The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study Cancer 89 2000 1555 1560
14. J. Shen-Gunther, and R.S. Mannel Ascites as a predictor of ovarian malignancy Gynecol Oncol 87 2002 77 83
15. U. Saygili, S. Guclu, T. Uslu, O. Erten, and E. Dogan The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma Int J Gynecol Cancer 12 2002 438 442
16. C. Miralles, M. Orea, P. Espana, M. Provencio, A. Sanchez, and B. Cantos Cancer antigen 125 associated with multiple benign and malignant pathologies Ann Surg Oncol 10 2003 150 154
17. D.K. Pauler, U. Menon, M. McIntosh, H.L. Symecko, S.J. Skates, and I.J. Jacobs Factors influencing serum CA125II levels in healthy postmenopausal women Cancer Epidemiol Biomarkers Prev 10 2001 489 493
18. C.C. Johnson, B. Kessel, T.L. Riley, L.R. Ragard, C.R. Williams, and J.L. Xu The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Gynecol Oncol 110 2008 383 389
19. A.R. Jeyarajah, T.E. Ind, S. Skates, D.H. Oram, and I.J. Jacobs Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women Cancer 85 1999 2068 2072
20. J.A. Chambers, and E. Solomon Isolation of the murine Nbr1 gene adjacent to the murine Brca1 gene Genomics 38 1996 305 313
21. B.B. Hermsen, S. von Mensdorff-Pouilly, J. Berkhof, P.J. van Diest, J.J. Gille, and F.H. Menko Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer J Clin Oncol 25 2007 1383 1389
22. C. Westhoff, E. Gollub, J. Patel, H. Rivera, and R. Bast Jr. CA 125 levels in menopausal women Obstet Gynecol 76 1990 428 431
23. I.K. Gipson, T. Blalock, A. Tisdale, S. Spurr-Michaud, S. Allcorn, and A. Stavreus-Evers MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence Biol Reprod 78 2008 134 142
24. Y. Haga, K. Sakamoto, H. Egami, R. Yoshimura, and M. Akagi Evaluation of serum CA125 values in healthy individuals and pregnant women Am J Med Sci 292 1986 25 29
25. L. Komlos, J. Landmann, J. Notmann, D. Aloni, F. Dulitzky, and J. Goldman Lymphocyte subpopulations in mother and newborn: correlation with sex of the newborn and number of pregnancies Gynecol Obstet Invest 27 1989 143 147
26. M. Muyldermans, F. Cornillie, and P. Koninckx CA125 and endometriosis Hum Reprod Update 1 1995 173 187
27. H. Ataseven, Z. Ozturk, M. Arhan, O. HYuksel, S. Koklu, and M. Ibis Cancer antigen 125 levels in inflammatory bowel diseases J Clin Lab Anal 23 2009 24408
28. A. Sarandakou, I. Phocas, D. Botsis, D. Rizos, E. Trakakis, and A. Chryssikopoulos Vaginal fluid and serum CEA, CA125 and SCC in normal conditions and in benign and malignant diseases of the genital tract Acta Oncol 36 1997 755 759
29. M.M. Gourevitch, S. von Mensdorff-Pouilly, S.V. Litvinov, P. Kenemans, G.J. van Kamp, and A.A. Verstraeten Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients Br J Cancer 72 1995 934 938
30. D.J. O'Rourke, D.A. DiJohnson, A.F. Vitonis, D.W. Cramer, and B.C.S. Liu Autoantibody signatures and immune complexes as potential biomarkers in ovarian cancer with low serum CA-125 Clin Chem 56 2010 A196